We describe the cardiovascular risk factors, clinical presentation, and prognosis in a comparative study of patients with peripheral artery disease (PAD) from the Cohorte des Patients ARTériopathes (COPART) cohort, which includes patients hospitalized for PAD in France. Among the 2514 patients included in the cohort, 189 had PAD before or at the age of 50 years and 2325 had it after. Young patients with PAD had diabetes less frequently (34% vs 46%, P < .001), were more frequent active smokers (58% vs 23%, P < 0.001), had lower high-density lipoprotein cholesterol (HDL-C; 41 ± 14 vs 44 ± 15 mg/dL, P = .026), and had a less frequent family and personal history of coronary heart disease. In a subset of 59 patients whose lipoprotein (a) (Lp(a)) was measured, the Lp(a) levels were higher in the young patients than in the older ones (89.7 mg/dL [9.7-151.3] vs 19.9 mg/dL [3.0-207.9], P = .004). Survival and amputation-free survival was 2.2 times higher (1.5-3.2, P < .001) in the young after 1 year. The onset of PAD before 50 years was associated with active smoking, low HDL-C, high Lp(a), and lower mortality.
CriquiMHFronekABarrett-ConnorEKlauberMRGabrielSGoodmanD. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71(3):510–515.
2.
HirschATCriquiMHTreat-JacobsonD. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–1324.
3.
SauvanierMConstansJSkopinskiS. Lower limb occlusive arteriopathy: retrospective analysis of 73 patients with onset before the age of 50 years. J Mal Vasc. 2002;27(2):69–76.
4.
ValentineRJJacksonMRModrallJGMcIntyreKEClagettGP. The progressive nature of peripheral arterial disease in young adults: a prospective analysis of white men referred to a vascular surgery service. J Vasc Surg. 1999;30(3):436–444.
5.
LaneJSVittinghoffELaneKTHiramotoJSMessinaLM. Risk factors for premature peripheral vascular disease: results for the National Health and Nutritional Survey, 1999-2002. J Vasc Surg. 2006;44(2):319–324; discussion 324-325.
6.
ValentineRJGuerraRStephanPScogginsEClagettGPCohenJ. Family history is a major determinant of subclinical peripheral arterial disease in young adults. J Vasc Surg. 2004;39(2):351–356.
7.
BérardAMBedelALe TrequesserR. Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study. PLoS One. 2013;8(3):e37882.
8.
CambouJPAboyansVConstansJLacroixPDentansCBuraA. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur J Vasc Endovasc Surg. 2010;39(5):577–585.
9.
ShionoyaS. Diagnostic criteria of Buerger’s disease. Int J Cardiol. 1998;66(suppl 1):S243–S245; discussion S247.
LevyPJGonzalezMFHornungCAChangWWHaynesJLRushDS. A prospective evaluation of atherosclerotic risk factors and hypercoagulability in young adults with premature lower extremity atherosclerosis. J Vasc Surg. 1996;23(1):36–43; discussion 43-45.
12.
DieplingerBLingenhelABaumgartnerN. Increased serum lipoprotein (a) concentrations and low molecular weight phenotypes of apolipoprotein (a) are associated with symptomatic peripheral arterial disease. Clin Chem. 2007;53(7):1298–1305.
13.
ValentineRJKaplanHSGreenRJacobsenDWMyersSIClagettGP. Lipoprotein (a), homocysteine, and hypercoagulable states in young men with premature peripheral atherosclerosis: a prospective, controlled analysis. J Vasc Surg. 1996;23(1):53–61; discussion 61-63.
14.
BucciMTanaCGiamberardinoMACipolloneF. Lp(a) and cardiovascular risk: Investigating the hidden side of the moon. Nutr Metab Cardiovasc Dis. 2016;26(11):980–986.
15.
HelgadottirAGretarsdottirSThorleifssonG. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60(8):722–729.
16.
HopewellJCClarkeRParishS. Lipoprotein(a) genetic variants associated with coronary and peripheral vascular disease but not with stroke risk in the Heart Protection Study. Circ Cardiovasc Genet. 2011;4(1):68–73.
17.
NaveAHLangeKSLeonardsCO. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis. 2015;242(2):496–503.
18.
AboyansVCriquiMHDenenbergJOKnokeJDRidkerPMFronekA. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113(22):2623–2269.
19.
ParhoferKG. Lipoprotein(a): medical treatment options for an elusive molecule. Curr Pharm Des. 2011;17(9):871–876.
20.
BallantyneCMShahSKherU. Lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low high-density lipoprotein cholesterol. Am J Cardiol. 2017;119(3):388–396.
21.
ValentineRJGrayburnPAVegaGLGrundySM. Lipoprotein(a) lipoprotein is an independent, discriminant risk factor for peripheral atherosclerosis among white men. Arch Intern Med. 1994;154(7):801–806.
22.
BoersGHJSmalsAGHTrijbelsFJM. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive disease. N Eng J Med. 1985;313(12):709–715.
23.
KulloIJLeeperNJ. The genetic basis of peripheral arterial disease. Current knowledge, challenges and future directions. Circ Res. 2015;116(9):1551–1560.
24.
WahlgrenCMManussonPK. Genetic influences on peripheral arterial disease in a twin population. Arterioscler Thromb vasc Biol. 2011;31(3):678–682.
